Accuray (ARAY) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS

Accuray (NASDAQ:ARAY) announced its earnings results on Tuesday, January 23rd. The medical equipment provider reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.05, Briefing.com reports. The business had revenue of $100.33 million for the quarter, compared to analysts’ expectations of $90.31 million. Accuray had a negative net margin of 6.09% and a negative return on equity of 44.66%. The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.11) EPS.

Accuray (ARAY) opened at $5.15 on Thursday. The company has a market cap of $435.00, a PE ratio of -17.76 and a beta of 1.77. Accuray has a one year low of $3.60 and a one year high of $6.15. The company has a current ratio of 1.54, a quick ratio of 0.99 and a debt-to-equity ratio of 2.66.

In other Accuray news, CFO Kevin Waters sold 7,154 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $5.06, for a total value of $36,199.24. Following the completion of the transaction, the chief financial officer now owns 335,087 shares in the company, valued at approximately $1,695,540.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Joshua Levine sold 17,093 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $4.86, for a total value of $83,071.98. Following the transaction, the chief executive officer now owns 1,435,428 shares of the company’s stock, valued at $6,976,180.08. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,413 shares of company stock valued at $129,798. Corporate insiders own 3.90% of the company’s stock.

Several equities research analysts have commented on ARAY shares. Zacks Investment Research upgraded shares of Accuray from a “hold” rating to a “buy” rating and set a $4.75 target price on the stock in a research report on Tuesday, October 24th. Cowen restated a “buy” rating and set a $9.00 target price on shares of Accuray in a research report on Friday, October 27th. Lake Street Capital started coverage on shares of Accuray in a research report on Thursday, November 30th. They issued a “buy” rating and a $10.00 price objective on the stock. BidaskClub lowered shares of Accuray from a “buy” rating to a “hold” rating in a research report on Tuesday, December 12th. Finally, JPMorgan Chase & Co. downgraded shares of Accuray from a “neutral” rating to an “underweight” rating and set a $6.00 target price for the company. in a research note on Wednesday, December 13th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $7.13.

COPYRIGHT VIOLATION WARNING: “Accuray (ARAY) Issues Quarterly Earnings Results, Beats Estimates By $0.05 EPS” was originally reported by Week Herald and is the sole property of of Week Herald. If you are viewing this article on another website, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The legal version of this article can be accessed at https://weekherald.com/2018/02/15/accuray-aray-releases-earnings-results.html.

Accuray Company Profile

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy.

Earnings History for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply